<SEC-DOCUMENT>0001193125-18-299767.txt : 20181016
<SEC-HEADER>0001193125-18-299767.hdr.sgml : 20181016
<ACCEPTANCE-DATETIME>20181016083458
ACCESSION NUMBER:		0001193125-18-299767
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181016
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181016
DATE AS OF CHANGE:		20181016

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CERUS CORP
		CENTRAL INDEX KEY:			0001020214
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				680262011
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21937
		FILM NUMBER:		181123577

	BUSINESS ADDRESS:	
		STREET 1:		2550 STANWELL DRIVE
		CITY:			CONCORD
		STATE:			CA
		ZIP:			94520
		BUSINESS PHONE:		9252886000

	MAIL ADDRESS:	
		STREET 1:		2550 STANWELL DRIVE
		STREET 2:		STE 300
		CITY:			CONCORD
		STATE:			CA
		ZIP:			94520

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CERUS TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19960731
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d632198d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, DC 20549</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of report (Date of earliest event reported): October&nbsp;16, 2018</B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>CERUS CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter)</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">000-21937</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">68-0262011</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2550 Stanwell Drive</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Concord, California</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>94520</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s Telephone Number, Including Area Code (925)
<FONT STYLE="white-space:nowrap">288-6000</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Former Name
or Former Address, if Changed Since Last Report)</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communication pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communication pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or
Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 (17 CFR <FONT STYLE="white-space:nowrap">&#167;240.12b-2).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company &#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act. &#9744; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Results of Operations and Financial Condition </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;16, 2018, Cerus Corporation (the &#147;Company&#148;) announced its preliminary product revenue results for the third quarter
ended September&nbsp;30, 2018. A copy of the Company&#146;s press release, entitled &#147;Cerus to Provide Update to Development Programs and Outline Growth Strategy at 2018 Institutional Investor Meeting,&#148; is furnished pursuant to Item 2.02 as
Exhibit 99.1 hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this report, including the exhibit hereto, shall not be deemed to be &#147;filed&#148; for
purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section&nbsp;11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the
accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, except as shall be expressly set forth by specific
reference in such filing. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
exhibit is furnished with this report: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d632198dex991.htm">Press release, dated October&nbsp;16, 2018, entitled &#147;Cerus to Provide Update to Development Programs and Outline Growth Strategy at 2018 Institutional Investor Meeting.&#148; </A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">CERUS CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: October&nbsp;16, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kevin D. Green</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kevin D. Green</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Vice President, Finance and
Chief Financial Officer</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d632198dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g632198g78q07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cerus to Provide Update to Development Programs and Outline Growth Strategy at 2018 Institutional
Investor Meeting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Announces preliminary Q3 product revenue of $15.4 million; raises full year revenue outlook </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONCORD, CA, October&nbsp;16, 2018&#151;Cerus Corporation (Nasdaq: CERS) is presenting its strategic roadmap and outlining its multi-year growth strategy at
the 2018 Cerus Institutional Investor Meeting today in Boston. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Our efforts to establish the INTERCEPT Blood System as the standard of care for
transfused blood components globally continue to gain traction,&#148; commented William &#145;Obi&#146; Greenman, Cerus&#146; president and chief executive officer. &#147;With the increasing visibility into our commercial opportunities and the
advances in our research and development pipeline, we believe that we are poised to sustain meaningful product revenue growth for the next several years.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Our preliminary Q3 product revenue of $15.4 million underscores the strong market demand for the INTERCEPT Blood System during the quarter, especially
in the U.S. Given our preliminary Q3 results, we are raising our full year product revenue guidance from a range of $56 million to $58 million to our <U>new range of $58 million to $60 million</U>, representing an increase of 33% to 38% compared to
2017 product revenue,&#148; continued Greenman. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Growth in 2018 has been largely driven by the conversion of the French platelet market to
INTERCEPT-treated platelets and from strong growth in the U.S.,&#148; noted Kevin D. Green, Cerus&#146; vice president and chief financial officer. &#147;As we look ahead to 2019, we anticipate revenue growth from continued U.S. market adoption,
with or without a final FDA guidance document on bacterial safety of platelets, and contribution from the German market toward the latter part of 2019. In 2020 and beyond, we anticipate revenue growth to accelerate due to the anticipated regulatory
approval and commercialization of our pipeline product candidates, including INTERCEPT red blood cells in Europe and extended storage pathogen-reduced cryoprecipitate.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agenda for today&#146;s meeting will cover the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INTERCEPT Red Blood Cells</B>: Dr.&nbsp;Richard Benjamin, Cerus&#146; chief medical officer will provide a framework on our U.S. and European clinical
development efforts and the timelines for regulatory submission. The Company is on track to submit its CE Mark filing by the end of this year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pathogen-Reduced Cryoprecipitate</B>: Dr.&nbsp;Laurence Corash, Cerus&#146; co-founder and chief scientific officer will outline the clinical rationale for
pathogen-reduced cryoprecipitate with a targeted post-thaw shelf life of five days compared to four to six hours for conventional cryoprecipitate. The Company anticipates submitting the PMA-supplement for pathogen-reduced cryoprecipitate in the
second half of 2019. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercial Update</B>: Vivek K. Jayaraman, Cerus&#146; chief commercial officer, will provide an update
on the Company&#146;s domestic and international growth opportunities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Update</B>: Kevin D. Green, Cerus vice president of finance and chief
financial officer will provide a framework on the Company&#146;s anticipated near to mid-term product revenue growth prospects, the potential impact of increasing kit volumes on gross margin, and the anticipated operating leverage from the
Company&#146;s commercial infrastructure as the business scales. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Guest speakers at today&#146;s meeting include: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Edward Snyder, Professor Laboratory Medicine, Yale University Medical School, Director, Blood and Tissue Bank Services. Dr.&nbsp;Snyder will discuss
Yale&#146;s experience with INTERCEPT platelets and the clinical need for pathogen-reduced red blood cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Melissa Cushing, Associate Professor
of Clinical Pathology and Laboratory Medicine at Weill Cornell Medical College, Associate Director of Clinical Laboratories and the Director of Transfusion Medicine and Cellular Therapy at New York-Presbyterian Hospital, Weill Cornell Campus.
Dr.&nbsp;Cushing will discuss the critical role of rapid cryoprecipitate transfusion in treating coagulopathy in bleeding patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Susan
Stramer, Vice President, Scientific Affairs, Biomedical Services, American Red Cross. Dr.&nbsp;Stramer will discuss the American Red Cross&#146; strategy and plans to more broadly roll-out pathogen-reduced platelets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Webcast Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A live webcast of Cerus&#146;
Institutional Investor Meeting will be available today, October&nbsp;16, starting at 9:30 a.m. E.T. and can be accessed from the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately
two weeks following the completion of the event. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ABOUT CERUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk
of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to
inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both
platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. See
http://www.cerus.com for information about Cerus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements and Preliminary Product Revenue Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Except for the historical statements contained herein, this press release contains forward-looking statements concerning Cerus&#146; products, prospects and
expected results, including statements concerning Cerus&#146; adjusted 2018 annual product revenue guidance; the potential contract value of Cerus&#146; amended agreement with BARDA; the potential to avoid septic platelet transfusions with the
INTERCEPT Blood System; the potential to expand the usage claims for the INTERCEPT Blood System; Cerus&#146; planned INTERCEPT red blood cell system CE Mark submission and the anticipated timing thereof; Cerus&#146; mission to establish INTERCEPT
Blood Systems as the standard of care for transfused blood components globally; Cerus&#146; belief that it is poised to sustain meaningful product revenue growth for the next several years; Cerus&#146; expectation for revenue growth in 2019 and in
2020 and beyond, and the anticipated reasons therefor; anticipated regulatory approval and commercialization of Cerus&#146; pipeline product candidates, including INTERCEPT red blood cells in Europe and extended storage pathogen-reduced
cryoprecipitate, and the anticipated timing thereof; Cerus&#146; planned INTERCEPT red blood cell system CE Mark submission and planned PMA supplement for extended storage pathogen-reduced cryoprecipitate, and the anticipated timing thereof;
Cerus&#146; expectations for increasing kit volumes and future operating leverage; and other statements that are not historical facts. Actual results could differ materially from these forward-looking statements as a result of certain factors,
including, without limitation: risks associated with the commercialization and market acceptance of, and customer demand for, the INTERCEPT Blood System, including the risks that Cerus may not (a)&nbsp;meet its adjusted revenue guidance for 2018,
(b)&nbsp;grow sales in its U.S. and European markets, including in France, and/or realize expected revenue contribution resulting from its U.S. and European market agreements, and/or (c)&nbsp;realize meaningful revenue contributions from U.S.
customers in the near term or at all, particularly since Cerus cannot guarantee the volume or timing of commercial purchases, if any, that its U.S. customers may make under Cerus&#146; commercial agreements with these customers; and/or
(d)&nbsp;realize any revenue contribution from its pipeline product candidates, whether due to Cerus&#146; inability to obtain regulatory approval of its pipeline product candidates, or otherwise; risks associated with Cerus&#146; lack of
commercialization experience in the United States and its ability to develop and maintain an effective and qualified U.S.-based commercial organization, as well as the resulting uncertainty of its ability to achieve market acceptance of and
otherwise successfully commercialize the INTERCEPT Blood System for platelets and plasma in the United States, including as a result of licensure requirements that must be satisfied by U.S. customers prior to their engaging in interstate transport
of blood components processed using the INTERCEPT Blood System; risks related to Fresenius Kabi&#146;s efforts to assure an uninterrupted supply of platelet additive solution (PAS); risks related to how any future PAS supply disruption could affect
INTERCEPT&#146;s acceptance in the marketplace; risks related to how any future PAS supply disruption might affect current commercial contracts; risks related to Cerus&#146; ability to demonstrate to the transfusion medicine community and other
health care constituencies that pathogen reduction and the INTERCEPT Blood System is safe, effective and economical; the uncertain and time-consuming development and regulatory process, including the risks (a)&nbsp;that Cerus may be unable to comply
with the FDA&#146;s post-approval requirements for the INTERCEPT platelet and plasma systems, including by successfully completing required post-approval studies, which could result in a loss of U.S. marketing approval for the INTERCEPT platelet
and/or plasma systems, (b)&nbsp;related to Cerus&#146; ability to expand the label claims and product configurations for the INTERCEPT platelet and plasma systems in the United States, including for INTERCEPT-treated extended storage cryoprecipitate
from plasma, which will require additional </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
regulatory approvals, (c)&nbsp;that Cerus may be unable to file for CE Mark approval of the red blood cell system in Europe on the anticipated timeframe or at all, and even if filed, Cerus may be
unable to obtain CE Mark approval, or any other regulatory approvals, of the red blood cell system in a timely manner or at all, (d)&nbsp;that Cerus may be unable to submit its planned PMA supplement to the FDA for INTERCEPT-treated extended storage
cryoprecipitate from plasma on the anticipated timeframe or at all, and even if submitted, Cerus may be unable to obtain FDA approval, or any other regulatory approvals, of INTERCEPT-treated extended storage cryoprecipitate from plasma in a timely
manner or at all, (e)&nbsp;that applicable regulatory authorities may disagree with Cerus&#145; interpretations of the data from its clinical studies and/or may otherwise determine not to approve Cerus&#146; regulatory submissions in a timely manner
or at all, and (f)&nbsp;that anticipated clinical trials of the INTERCEPT Blood System may not be initiated on the anticipated timing or at all, or if initiated, may be extended, delayed, suspended or terminated, including as result of safety
concerns; risks associated with the uncertain nature of BARDA&#146;s funding over which Cerus has no control as well as actions of Congress and governmental agencies which may adversely affect the availability of funding under Cerus&#146; BARDA
agreement and/or BARDA&#146;s exercise of any potential subsequent option periods, such that the anticipated activities that Cerus expects to conduct with the funds available from BARDA may be delayed or halted and that Cerus may not otherwise
realize the total potential value under its agreement with BARDA; risk related to product safety, including the risk that the septic platelet transfusions may not be avoidable with the INTERCEPT Blood System; risks related to adverse market and
economic conditions, including continued or more severe adverse fluctuations in foreign exchange rates and/or weakening economic conditions in the markets where Cerus currently sells and is anticipated to sell its products; Cerus&#146; reliance on
third parties to market, sell, distribute and maintain its products; Cerus&#146; ability to maintain an effective manufacturing supply chain, including the ability of its manufacturers to comply with extensive FDA and foreign regulatory agency
requirements, and Cerus&#146; ability to maintain its primary kit manufacturing agreement and its other supply agreements with its third party suppliers; the impact of legislative or regulatory healthcare reforms that may make it more difficult and
costly for Cerus to produce, market and distribute its products; risks related to future opportunities and plans, including the uncertainty of Cerus&#146; future capital requirements and its future revenues and other financial performance and
results, as well as other risks detailed in Cerus&#146; filings with the Securities and Exchange Commission, including Cerus&#146; Quarterly Report on Form 10-Q for the quarter ended June&nbsp;30, 2018, filed with the SEC on August&nbsp;2, 2018.
Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press
release includes Cerus&#146; preliminary product revenue results for the quarter ended September&nbsp;30, 2018. Cerus is currently in the process of finalizing its full financial results for the quarter ended September&nbsp;30, 2018, and the
preliminary product revenue results presented in this press release is based only upon preliminary information available to Cerus as of October&nbsp;16, 2018. Cerus&#146; preliminary product revenue results should not be viewed as a substitute for
full interim financial statements prepared in accordance with U.S. GAAP, and undue reliance should not be placed on Cerus&#146; preliminary product revenue results. In addition, Cerus&#146; independent registered public accounting firm has not
reviewed the preliminary product revenue results included in this press release or expressed any opinion or other form of assurance on such preliminary product revenue results. In addition, items or events may be identified or occur after the date
hereof due to the completion of operational and financial closing procedures, final </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
adjustments and other developments may arise that would require Cerus to make material adjustments to the preliminary product revenue results included in this press release. Therefore, the
preliminary product revenue results included in this press release may differ from the product revenue results that will be reflected in Cerus&#146; complete condensed consolidated financial statements for the three months ended September&nbsp;30,
2018. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contact: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim Lee &#150; Investor Relations
Director </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cerus Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">925-288-6137 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">5 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g632198g78q07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g632198g78q07.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M)H%AJMS  1Y$D]O'*Z8/(PS$<^E==4=G9PZ=:16]O%'!;P((XXXU"I&H& H
MX  X %24$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
%10!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
